Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
By Barbara Obstoj-Cardwell. Editor
Teva Pharmaceuticals’ announcement on Monday that it will voluntarily suspend sales, marketing and distribution of its Zecuity migraine relief product will likely have little impact on the company, analysts have said. 19 June 2016
The global market for geriatric medicines is expected to reach a value of over $1,017 billion by 2024, according to a new report by Grand View Research Inc. 14 June 2016
Israeli drugmaker Teva Pharmaceutical Industries said today that it will voluntarily suspend sales, marketing and distribution of its migraine treatment Zecuity (sumatriptan iontophoretic transdermal system) due to observed negative side effects. 13 June 2016
US biopharma company Marinus Pharmaceuticals saw its share plummet today after it announced disappointing top-line results from its Phase III clinical trial in adults with drug-resistant focal onset seizures. 13 June 2016
Amgen’s experimental migraine drug erenumab has met the main goal of a midstage study by reducing the number of monthly attacks compared with a placebo. 10 June 2016
AstraZeneca has entered into a commercialization agreement with Aspen Global Incorporated (AGI), part of the South Africa’s Aspen Group, for rights to its global anesthetics portfolio outside the USA. 10 June 2016
US Food and Drug Administration advisory panels yesterday voted 14 to three to recommend approval of Vantrela ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. 8 June 2016
Shares of US biotech major Biogen fell around 8.8% to $289.84 in pre-market trading Tuesday after the company released disappointing trial results with its potentially transformative multiple sclerosis drug candidate opicinumab. 7 June 2016
UK based Indivior on Friday received a favorable ruling in the District Court of Delaware in the ANDA litigation against Actavis Laboratories and Par Pharmaceutical relating to Suboxone (buprenorphine and naloxone) its treatment for opioid addiction. 4 June 2016
The European Medicines Agency (EMA) has accepted aducanumab, an investigational treatment for early Alzheimer’s disease being developed by US biotech major Biogen, into its Priority Medicines (PRIME) program. 2 June 2016
Teva Pharmaceutical Industries has been asked to provide more information on its New Drug Application for SD-809 (deutetrabenazine) tablets for the treatment of chorea associated Huntington disease (HD) by the US Food and Drug Administration. 1 June 2016
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has asked Janssen, to set out a case for including its leukemia drug Imbruvica (ibrutinib) in the Cancer Drugs Fund (CDF). 1 June 2016
The US Food and Drug Administration on Friday approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). 31 May 2016
Minerva Neurosciences saw its shares make massive gains on Thursday following the release of positive results from a couple of mid-stage clinical trials. 31 May 2016
Eisai announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan this month. 25 May 2016
In a presentation to the investment community today, US pharma major Eli Lilly said it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. 24 May 2016
Shares of US drugmaker XenoPort rocketed 56.59% to $6.89 on Monday on the news that Arbor Pharmaceuticals plans to acquire the company in a deal valuing it at about $467 million. 24 May 2016
US specialty pharma firm Egalet says it has reached an agreement with Purdue Pharma as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals for Oxaydo (oxycodone HCl, USP) tablets CII. 23 May 2016